Chris Schott analyst JPMORGAN

Currently out of the existing stock ratings of Chris Schott, 7 are a SELL (4.05%), 41 are a HOLD (23.7%), 125 are a BUY (72.25%).

Chris Schott

Work Performance Price Targets & Ratings Chart

Analyst Chris Schott, currently employed at JPMORGAN, carries an average stock price target met ratio of 42.46% that have a potential upside of 19.7% achieved within 249 days.

Chris Schott’s has documented 360 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 13-Nov-2024.

Wall Street Analyst Chris Schott

Analyst best performing recommendations are on EQRX (EQRX).
The best stock recommendation documented was for EQRX (EQRX) at 8/16/2022. The price target of $5.5 was fulfilled within 3 days with a profit of $0.67 (13.87%) receiving and performance score of 46.24.

Average potential price target upside

ABBV AbbVie BHC Bausch Health Companies BMY Bristol-Myers Squibb Company HZNP Horizon Pharma PLC IDXX IDEXX Laboratories JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany PFE Pfizer TEVA Teva Pharma Industries Ltd ADR ELAN Elanco Animal Health HSKA Heska MYL Viatris AGN Allergan plc CHRS Coherus BioSciences MNK Mallinckrodt plc RPRX Royalty Pharma Plc VTRS Viatris EQRX EQRx ZTS Zoetis ENDP Endo International PLC PRGO Perrigo Company PLC REGN Regeneron Pharmaceuticals TXMD TherapeuticsMD KALA Kala Pharmaceuticals OGN Organon PCRX Pacira Pharmaceuticals BIIB Biogen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$191

$16.81 (9.65%)

4 days ago
(10-Dec-2024)

3/4 (75%)

$15.34 (8.73%)

764

Hold

$191

$16.81 (9.65%)

$205

4 days ago
(10-Dec-2024)

2/4 (50%)

$15.34 (8.73%)

507

Hold

$206

$31.81 (18.26%)

$153

22 days ago
(22-Nov-2024)

13/14 (92.86%)

$27.92 (15.68%)

293

Buy

$200

$25.81 (14.82%)

$190

1 months 1 days ago
(13-Nov-2024)

12/13 (92.31%)

$28.57 (16.67%)

490

Buy

$215

$40.81 (23.43%)

$226

1 months 2 days ago
(12-Nov-2024)

8/10 (80%)

$39.86 (22.76%)

293

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Chris Schott is most bullish on?

Potential upside of $418.7 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Chris Schott is most reserved on?

Potential downside of $1.5 has been obtained for TEVA (TEVA PHARMA INDUSTRIES LTD ADR)

What Year was the first public recommendation made by Chris Schott?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?